NCT02659657

Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation

Prophylaxis Roles of Low Dose of IL-2 Treatment on GVHD After Haploidentical Transplantation

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 15 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow transplantation (HBMT) on hematological malignancies are well established.The aim of this prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be decreased with IL2 therapy post HBMT.

Detailed description

The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow transplantation (HBMT) on hematological malignancies are well established.The aim of this prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be decreased with IL2 therapy post HBMT.low dose of IL-2 (40 million U/m2) will be administered from WBC engraftment to day 90 post haploidentical transplantation. IL-2 will be administered three times a week.

Conditions

• Acute Graft-versus-host Disease

Interventions

Type	Name	Description
DRUG	Interleukin-2	Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)

Timeline

• Start date: 2015-03-01
• Primary completion: 2021-06-01
• Completion: 2021-12-01
• First posted: 2016-01-20
• Last updated: 2020-10-01

Locations

1 site across 1 country: China